Table 2 Overview of in vivo studies based on CAR-NK cell therapy for hematological malignancies
From: CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies
Condition | Target | Main results | Ref |
|---|---|---|---|
B cell malignancies | CD19 | Prolonged survival in a xenograft Raji lymphoma murine model upon injection iC9/CAR.19/IL-15-transduced CB NK cells which produce IL-15 to improve their function | [148] |
B cell precursor acute lymphoblastic leukemia | CD19 | Potent antileukemia activity of human lymphoma in (NSG) xenograft mice model by CAR-CD19-PB NK cells | [154] |
B cell leukemia and lymphoma | CD19 | Abrogation of disease progression with selective cytotoxicity against Raji B cell lymphoma xenograft NSG mice model upon injection of NK-92/63.z cells | [64] |
B cell acute lymphoblastic leukemia (BLL) | CD19 | Complete molecular remission and prolonged survival in B cell lymphoma xenograft (NSG) mice model by CD19-CAR-NK cells | [155] |
Lymphoma and leukemia | CD19 & CD20 | Eradication of TMD-5 (CD19 + CD20+) cells by Intrafemoral injection of CD19-CAR NK-92 and eliminating BCR-ABL1+ SUP-B15 (CD19 + CD20−) cells by intravenous injection of CD19-CAR NK-92 in xenotransplant mouse models Effective suppressing local tumor development in Daudi lymphoma xenograft mice model by CD20-CAR NK-92 than CD19-CAR NK-92 | [158] |
B cell non-Hodgkin’s lymphomas (NHL) | CD20 | Inhibiting MAVER-1 tumor cell growth in xenograft NCG mice model with NK- 92MI cells expressing receptor of CD16-BB-ζ | [159] |
CD20+ B cell non-Hodgkin’s lymphomas (NHL) | CD20 | Reducing tumor size and extended survival in Raji-Luc and Raji-2R-Luc xenograft NSG mice model upon injection of CD20-CAR-PB NK cells | [160] |
Burkitt Lymphoma | CD20 | The combination of romidepsin and CD20-CAR-PB NK cells reduced tumor burden and enhanced survival in humanized BL in xenograft NSG mice models | [161] |
Pre-B cell acute lymphoblastic leukemia (B-ALL) | FLT3 | Abrogated disease progression, high antileukemic activity, and enhancing safety by NK-92 cells co-expressing the FLT3-specific CAR and iCasp9 in a B-ALL xenograft model in NSG mice | [162] |
T cell acute lymphoblastic leukemia | CD5 | Abrogated disease progression and improved survival with CD5-CAR-NK-92 cells in xenograft mouse models of CD5+ T-ALL | [163] |
T cell malignancies | CD5 | A significant decrease in tumor burden was observed with CD5-CAR-expressing NK-92 cells in a T cell leukemia xenograft mouse model | [164] |
T cell malignancies | CD5 | CD5-CAR-NK cells with costimulators 2B4 showed superior cytotoxic ability against T-ALL in mouse xenograft models and prolonged the survival of T-ALL xenograft mice than CD5-CAR-NK with costimulators 4-1BB | [98] |
T cell non-Hodgkin’s lymphomas (NHLs) | CD4 | CD4-CAR-NK-92 cells significantly reduced tumor burden and prolonged survival in KARPAS-299-injected NSG mice | [165] |
Multiple myeloma | CS1 | Suppressing the growth of human IM9 MM cells and also significantly prolonged survival in an aggressive orthotopic MM xenograft mouse model upon injection of CS1-CAR-NK-92 cells | [166] |
Multiple myeloma | CD138 | Marked antitumor activity toward CD138+ MM cells in the xenograft SCID mouse model by CD138-CAR-NK-92MI cells | [167] |
Acute myeloid leukemia (AML) | CD123 | Significantly reduced disease burden in NSG mice xenografted with luciferase-expressing THP-1 cells upon injection of CD123-CAR-NK-92 | [171] |
Acute myeloid leukemia (AML) | CD4 | Antileukemic effects in a systemic AML murine model with CD4-CAR-PB NK cells | [173] |